Infliximab Combined with Enteral Nutrition for Managing Crohn’s Disease Complicated with Intestinal Fistulas

Table 1

The clinical characteristics of 42 patients with CD.

Clinical features	Conventional group ()	IFX group ()
Average age (year)	32.1 ± 11.8	31.6 ± 11.7
Sex (male, %)	13 (59%)	12 (60%)
Average CDAI score	309.9 ± 69.3	325.6 ± 70.8
Duration of disease
<12 months	2 (9.1%)	2 (10.0%)
12–36 months	14 (63.6%)	13 (65.0%)
>36 months	6 (27.3%)	5 (25.0%)
Lesion site
Terminal ileum (L1 type)	6 (27.3%)	6 (30.0%)
Colon (L2 type)	7 (31.8%)	6 (30.0%)
Ileum and colon (L3 type)	9 (40.9%)	8 (40.0%)
Disease behavior
No stenosis or penetration (B1 type)	0 (0%)	0 (0%)
Stenosis (B2 type)	0 (0%)	0 (0%)
Penetration (B3 type)	22 (100%)	20 (100%)
Stage of disease activity
Moderate active stage	14 (63.6%)	13 (65.0%)
Severe active stage	8 (36.4%)	7 (35.0%)
Combined drug therapy
5-Aminosalicylic acid	22 (100%)	20 (100%)
Methylprednisolone	22 (100%)	0 (0%)
Imuran	22 (100%)	0 (0%)
Associated with anal lesions	16 (72.7%)	14 (70.0%)
History of intestinal surgery	5 (22.7%)	6 (30.0%)
Extraintestinal manifestations	4 (18.2%)	4 (20.0%)

Compared with the IFX treatment group: .